ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2 Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A251

Its studies are led by HUTCHMED.

Furthest: phase 2, since Nov 11, 20251 company-led study, 1 open or runningNext primary completion: Nov 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED11 open or runningphase 2since Nov 11, 2025Nov 11, 2025Nov 30, 2028phase 2 · NCT07228247

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2025First study: phase 2 study in Solid Tumors, AdultFirst studyNCT07228247 · 147 planned · United States, China

Ahead

  1. Nov 30, 2028Primary completion: phase 2 study in Solid Tumors, AdultNCT07228247

TargetBeta

ERBB2 →read by rule
“An antibody-targeted therapy conjugate (ATTC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the receptor tyrosine kinase human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07228247Solid Tumors, Adult · United States, China2RecruitingNov 30, 2028147

How it is read

Names in the registry

  • “HMPL-A251”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.